Next Article in Journal
Discovery of Uracil Derivatives as Potent Inhibitors of Fatty Acid Amide Hydrolase
Previous Article in Journal
Screening and Analysis of the Potential Bioactive Components of Poria cocos (Schw.) Wolf by HPLC and HPLC-MSn with the Aid of Chemometrics
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 21
Issue 2
10.3390/molecules21020228
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Synthesis and Structure-Activity Relationships of Imidazole-Coumarin Conjugates against Hepatitis C Virus

by
Shwu-Chen Tsay
1,2,*,
Shu-Yu Lin
1,
Wen-Chieh Huang
1,
Ming-Hua Hsu
1,
Kuo Chu Hwang
1,
Chun-Cheng Lin
1,
Jia-Cherng Horng
1,
I-Chia Chen
1,
Jih Ru Hwu
1,2,*,
Fa-Kuen Shieh
2,
Pieter Leyssen
3 and
Johan Neyts
3,*
1
Department of Chemistry & Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu 30013, Taiwan
2
Department of Chemistry, National Central University, Jhongli District, Taoyuan City 32001, Taiwan
3
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Minderbroedersstraat 10, Leuven B-3000, Belgium
*
Authors to whom correspondence should be addressed.
Molecules 2016, 21(2), 228; https://doi.org/10.3390/molecules21020228
Submission received: 21 January 2016 / Revised: 4 February 2016 / Accepted: 4 February 2016 / Published: 18 February 2016
(This article belongs to the Section Medicinal Chemistry)
Browse Figures
Versions Notes

Abstract

:
A series of new conjugated compounds with a –SCH2– linkage were synthesized by chemical methods from imidazole and coumarin derivatives. The experimental results indicate that of the twenty newly synthesized imidazole–coumarin conjugates, three of them exhibited appealing EC50 values (5.1–8.4 μM) and selective indices >20 against hepatitis C virus. Their potency and selectivity were increased substantially by modification of their structure with two factors: imidazole nucleus with a hydrogen atom at the N(1) position and coumarin nucleus with a substituent, such as Cl, F, Br, Me, and OMe. These guidelines provide valuable information for further development of conjugated compounds as anti-viral agents.

Graphical Abstract

1. Introduction

Hepatitis C virus (HCV) infection afflicts ~150 million people worldwide (~3% of the global population), with approximately 3–4 million new cases occurring annually [1]. HCV generally causes both mild and acute liver disease, possibly leading to cirrhosis, hepatocellular carcinoma, and liver failure. The traditional therapeutic treatment involves administering interferon α-2 or its PEGylated form, either alone or in combination with ribavirin [2,3]. In 2011, boceprevir and telaprevir were approved for the treatment of chronic hepatitis C genotype 1 infection in combination with peg-interferon α and ribavirin. The recommended treatment regimens have significantly increased the overall cure rates [4,5]. The above therapeutic treatments, however, still have substantial adverse effects [6]. During the past two years, the U.S. Food and Drug Administration has approved Harvoni™ (ledipasvir/sofosbuvir), simeprevir, sofosbuvir, and Viekira Pak™ (ombitasvir/paritaprevir/ritonavir tablet; dasabuvir tablet). Harvoni™ and Viekira Pak™ are combination pills in which each of the active ingredients therein has a distinct mechanism of action (MOA) [7,8]. As new generation drugs for the treatment of HCV infections, the recommended 12- or 24-week courses of therapy of both are highly expensive [9]. Thus, pharmaceutical companies are still seeking chemical entities with safer and lower price than the existing drugs to combat the HCV disease. Our recent works introduced a series of coumarin-containing conjugated compounds as new anti-HCV agents, including benzimidazole–, heterobicycle–, and (ribosyl)purine–coumarin conjugates [10,11,12,13,14]. The aim of this work was to synthesize new compounds with a scaffold containing a coumarin moiety that is conjugated with an imidazole moiety or its derivatives, including (1-ribofuranosyl)imidazole, inosine, and guanosine. Their anti-HCV activity is to be explored and their structure–activity is to be deduced.
Coumarins belong to an important family of compounds with various pharmacological functions [15,16]. Despite the development of their derivatives as HCV NS3·4A protease inhibitors and NS5B polymerase inhibitors [15,17], the flat and shallow substrate-binding groove of proteases inhibits their potency and selectivity [18,19].
Imidazole derivatives and imidazole-2-thiones represent a class of compounds with important pharmacological properties, including anti-bacterial [20], anti-inflammatory [21], anti-cancer [22], and anti-viral activities [23,24]. In the histidine moieties of enzymes, the imidazole ring functions as a proton donor or acceptor or both in enzymic reactions in the charge-relay system when it is in a free base form [25]. Therefore, many well-known biocatalysts possess this moiety. Several investigations have elucidated the N-alkylation of imidazole compounds, which alter the pharmacological actions and pharmacokinetics [26,27].
In 2010, Zai and co-workers [28] reported that inosine alters gene expression and axonal projections in neurons contralateral to a cortical infarct. Additionally, it exerts a broad range of anti-inflammatory effects in a murine model of acute lung injury, as found by Liaud et al. [29]. Inosine is also the major component of the drug isoprinosine for the treatment of chronic hepatitis B. This drug inhibits replication of many RNA and DNA viruses in vivo and in vitro [30]. It also exerts an immunostimulatory effect by enhancing T-cell function and macrophage activity [31]. Containing inosine as a major component, the drug Isoprinosine unfortunately exhibits several side effects [32]. Those effects include dyspepsia, hypersensitivity reactions, and severe drug reactions with ribavirin that may result in a drop in the white blood cell count of patients.
Giuliani and co-workers [33] recognized protective activity of guanosine in an in vitro model of Parkinson’s disease. Very recently, Gosselin et al. [34] reported a 2′-C-methyl branched guanosine pro-nucleotide as a potent liver-targeted HCV polymerase inhibitor. Schaefer–Korting et al. [35] found that a guanosine-analog phosphonate can improve topical non-melanoma skin cancer treatment.
This work extends the range of available benzimidazole–coumarin conjugates by replacement of the benzimidazole moiety therein with an imidazole moiety or its derivatives (i.e., inosine and guanosine). An attempt is also made to understand how they influence the anti-HCV activity of the conjugated compounds by use of three structural relatives, namely N-H, N-methyl, and N-ribofuranosyl imidazoles. Additionally, various substituents (i.e., F, Cl, Br, Me, and OMe) are attached to the coumarin moiety. In total, 20 imidazole–coumarin conjugated compounds with the common skeleton shown in Figure 1 below were synthesized and their structure–activity relationships derived.

2. Results and Discussion

2.1. Chemistry

To investigate the effects of different moieties or functional groups attached to the core, our research group synthesized four series of imidazole–coumarin conjugated compounds. The corresponding synthetic procedures are described as follows.

2.1.1. Synthesis of Imidazole–Coumarin Conjugates

Conjugates with a coumarin moiety attached at the C(2)-position of the imidazole group via a thiomethylene joint were synthesized. Correspondingly, 1H-imidazole-2-thiol (1a) was coupled with various 3-(chloromethyl)coumarins 2 in the presence of aqueous ammonia and acetonitrile. Conjugates 3a–e with different substituents (e.g., F, Cl, Br, and OMe) were obtained in 65%–86% yields. Furthermore, their methyl analogs (i.e., 3f and 3g) were prepared by alkylation of 1-methylimidazole-2-thiol (1b) with coumarins 2a and 2c, respectively. Under these alkaline conditions, the NH group of 1 did not compete with the C(2)-thiol group for nucleophilic attack of the coumarin substrates [12] (Scheme 1).

2.1.2. Synthesis of (1-Ribofuranosyl)imidazole–Coumarin Conjugates

Nucleoside derivatives are promising candidates for anti-viral drugs [36,37], which explains our intention to prepare (1-ribofuranosyl)imidazole–coumarin conjugates for an anti-viral activity assay. First, silylation of 1H-imidazole-2-thiol (1a) with N,O-bis(trimethylsilyl)acetamide (BTSA) [38] gave the intermediates, which were then coupled with 1,2,3,5-tetra-O-acetyl-β-d-ribofuranose (4) in the presence of Me3SiOTf and acetonitrile at 80 °C. Subsequent removal of the three acetyl groups in 5 with K2CO3 in methanol provided the resultant thiol 6. Its coupling [39] with coumarins 2 produced (1-ribofuranosyl)imidazole–coumarin conjugates 7 in good yields (72%–84%) (Scheme 2).

2.1.3. Synthesis of Inosine– and Guanosine–Coumarin Conjugates

We found that the desired SN2 reactions occurred at the thiol group of compounds 8 [40] and 10 [41] with the allylic position of 3-(chloromethyl)coumarins 2 to give the desired conjugated products 9 and 11, respectively. The unwanted Michael addition did not occur at the α,β-unsaturated lactone moiety of coumarins 2. The key factors for success involved the use of 35% aqueous ammonia and acetonitrile as the media at room temperature. Accordingly, yields of 70%–83% for inosine–coumarins 9 and 74%–89% for guanosine–coumarins 11 were obtained (Scheme 3).

2.1.4. Identification of the Structures of New Conjugated Compounds

The structures of all newly synthesized compounds were confirmed on the basis of their spectroscopic characteristics. For instance, the IR spectrum of conjugates 7a displayed a strong absorption band at 1698 cm−1 , which was contributed to the carbonyl stretching vibration of the coumarin moiety [42]. Its 13C-NMR spectrum had resonances at 34.27 and 151.94 ppm for the SCH2 carbon and the –N=C(–N)(–S) carbons, respectively. Furthermore, a doublet with J = 7.2 Hz occurred at 5.67 ppm for the glycosidic proton [43] in its 1H-NMR spectrum. Nevertheless, it was beyond our expection that the two characteristic singlets, instead of doublets, occurred at 7.49 and 6.99 ppm for the protons in the imidazole nucleus. Our data are in consistent with those of N-(β-d-ribofuranosyl)imidazole, the parent compound of 7a, as reported by Mourabit and co-workers [44].
In addition, a doublet with J = 6.4 Hz at 5.76 ppm in the 1H-NMR spectrum was assigned as the anomeric hydrogen of compound 9a. They also exhibited two characteristic doublets at 4.39 and 4.34 ppm with J = 14.2 Hz for the two SCH2 hydrogens and a singlet at 8.06 ppm for the NH–CH=N proton in inosine moiety. In its 13C-NMR spectrum, resonance occurred at 32.04 ppm for the SCH2 carbon.

2.2. Pharmacology

Anti-HCV Activity

The antiviral activity of conjugated compounds 3a–g, 7a–e, 9a,b,d–f, and 11b,e,f in the HCV genotype 1b subgenomic Huh 5-2 replicon system [45] was evaluated according to established procedures [46]. On the basis of the dose-response curves that were obtained, the concentration of a compound that inhibited virus replication by 50% (i.e., EC50) and the concentration of compound that reduced host cell metabolism by 50% (i.e., CC50) were obtained. These values subsequently allowed us to calculate the selectivity index (i.e., SI = CC50/EC50), which is a measure for the therapeutic window of the compound in an assay system. Compounds were only considered as selective inhibitors in the replicon assay when virus RNA replication was significantly inhibited (>70%) at concentrations not adversely affecting the host cell metabolism. The observed antiviral effect of other compounds was most likely related mainly to the pleiotropic or aspecific effect on the host cell.
Of the 20 newly synthesized conjugates, five (i.e., 3b–f) exhibited appealing antiviral activity with EC50 values of 5.1–9.7 μM in the HCV 1b Huh 5-2 replicon system (Table 1). Three conjugates 3b, 3d, and 3e displayed a significant window of selectivity with SI of 12–21.

3. Structure–Activity Relationship: Essential Moieties and Functional Groups

This work established four new sets of conjugated compounds in the family of imidazole–, (1-ribofuranosyl)imidazole–, inosine–, and guanosine–coumarins as shown in Scheme 1, Scheme 2 and Scheme 3. All of the conjugates had a –SCH2– joint to connect a coumarin moiety to an imidazole moiety. The substituents in these conjugated compounds included F, Cl, Br, Me, and OMe. Close examination of their EC50, CC50, and SI values shown in Table 1 allows us to deduce their SAR.
Attachment of the coumarin moiety to the imidazole nucleus generated conjugates with important anti-HCV activity. Successful examples include 3b–e with EC50 = 5.1–9.7 μM and SI = 8.8–21. Besides, attachment of a substituent (e.g., F, Cl, Br, and OMe) to the coumarin nucleus increased the potency and the SI value by a factor of 2.1–5.1 (cf. 3b–e vs. 3a).
An Me group could be introduced onto the imidazole nucleus, while the resultant conjugates without an N–H proton maintained a similar order of anti-HCV activity and selectivity (cf. 3f and 3g with EC50 = 6.7 and 15 μM, respectively; SI = 7.3 and 5.1, respectively). On the other hand, introduction of a β-d-ribofuranosyl moiety to the thiomethylene-linked imidazole–coumarin conjugates led to a triply hybrid compound (i.e., 7a–e), some of which also exhibited anti-HCV activity (EC50 = 14 and 19 μM for 7c and 7d, respectively). In contrast to the ribosylated form at the N(1) position of the imidazole nucleus, the N–H group at that position allowed for an incremental SI value (cf. 3a–e vs. 7a–e). Accordingly, the imidazole nucleus bearing an H was considered as an ideal core for conjugation with coumarins.
The conjugated compounds with the imidazole nucleus had a higher selectivity than those (i.e., 12a,d,e) [11] with a benzimidazole nucleus as shown below (Figure 2). It is due to lower cytotoxicity associated with the conjugates 3a,d,e (cf. 3a vs. 12a, 3d vs. 12d and 3e vs. 12e). Moreover, the conjugated compounds bearing a simple imidazole nucleus showed greater anti-HCV activity than the corresponding conjugated compounds bearing an inosine or a guanosine nucleus by one order (cf. 3 vs. 9, and 3 vs. 11).

4. Experimental Section

4.1. General Procedures

All reactions were carried out in oven-dried glassware (120 °C) under an atmosphere of nitrogen unless indicated otherwise. Dichloromethane, acetone, and methanol were purchased from Mallinckrodt Chemical Co. (Dublin, Ireland). Acetonitrile was purchased from Fischer Scientific Co. (Hampton, NH, USA). Ethyl acetate (EtOAc) and hexanes from Mallinckrodt Chemical Co. were dried and distilled from CaH2. Trimethylsilyl trifluoro-methanesulfonate (Me3SiOTf) was purchased from Fluka Chemika (St. Louis, MO, USA). N,O-Bistrimethylsilylacetamide (BTSA) was purchased from Merck & Co. (Kenilworth, NJ, USA). Aqueous ammonium hydroxide was purchased from J. T. Baker Chemical Co. (Center Valley, PA, USA). p-Toluenesulfonic acid monohydrate (PTSA), 1H-imidazole-2-thiol (1a), and 1-methyl-imidazole-2-thiol (1b) were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). 1,2,3,5-Tetra-O-acetyl-β-d-ribofuranose was purchased from Alfa Aesar Chemical Co. (Ward Hill, MA, USA). 3-(Chloromethyl)coumarins [47] 2a–e, 8-mercaptoinosine 8 [40], and 8-mercaptoguanosine 10 [41], were prepared according to the reported methods.
Melting points were obtained with a MP-2D melting point apparatus (Fargo, New Taipei City, Taiwan). Analytical thin layer chromatography (TLC) was performed on pre-coated plates (silica gel 60 F-254) purchased from Merck & Co. (Kenilworth, NJ, USA). Purification by gravity column chromatography was carried out by use of Silicycle (Quebec, QC, Canada) ultra pure silica gel (particle size 40–63 μm, 230–400 mesh). High performance liquid chromatography (HPLC) was performed on two Waters 515 HPLC pumps equipped with a Waters 2489 UV/visible detector (Milford, MA, USA) and a Thermo (Waltham, MA, USA) 5 μm Hypersil ODS (250 mm × 4.6 mm i.d.). Purity of all compounds was >98.0%, as checked by HPLC.
Infrared (IR) spectra were measured on a model Spectrum One B spectrophotometer (Perkin-Elmer, Waltham, MA, USA). Absorption intensities are recorded with the following abbreviations: s, strong; m, medium; w, weak. High-resolution mass spectra were obtained by means of a JMS-700 mass spectrometer (JEOL, Tokyo, Japan). Proton NMR spectra were obtained on a Mercury-400 (400 MHz) spectrometer (Varian, Palo Alto, CA, USA) or an AC-400 (400 MHz) spectrometer (Bruker, Billerica, MA, USA) using chloroform-d, or dimethylsulfoxide-d6 as solvents. Proton NMR chemical shifts are referenced to the CHCl3 singlet (δ 7.24 ppm), and the center of DMSO-d6 quintet (δ 2.49 ppm). Carbon-13 NMR spectra were recorded on a Varian Mercury-400 (100 MHz) spectrometer or Bruker AC-400 (100 MHz) spectrometer using chloroform-d, dimethylsulfoxide-d6, or pyridine-d5 as solvents. Carbon-13 chemical shifts are referenced to the center of the CDCl3 triplet (δ 77.0 ppm), the DMSO-d6 septet (δ 39.5 ppm), and the pyridine-d5 triplet (δ 150.4 ppm). Multiplicities are recorded with the following abbreviations: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; J, coupling constant (hertz).

4.2. Standard Procedure for the Synthesis of Imidazole–Coumarin Conjugates 3, 7, 9, and 11

To a solution containing a thione (1, 6, 8, or 10, 1.0 equiv) in water (2.5 mL) and acetonitrile (1.5 mL) was added saturated aqueous ammonium hydroxide. After the solution was stirred at room temperature for 30 min, a 3-(chloromethyl)coumarin (2, 1.5 equiv) was added and stirring was continued at room temperature for 15 min to 2.0 h. Acetonitrile therein was removed under reduced pressure and water was further removed under reduced pressure over P2O5 with a Kügelrohr GKR-51 apparatus (BUCHI, Flawil, Switzerland). The residue was purified by use of column chromatography packed with silica gel to give the desired products with purity of >98.0%, as determined by HPLC (see Supplementary Materials).

4.2.1. 2-[(Coumarin-3’-yl)methylthio]imidazole (3a)

The standard procedure was followed by use of 1H-imidazole-2-thiol (1a, 28.6 mg, 0.286 mmol, 1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)coumarin (2a, 66.7 mg, 0.343 mmol, 1.2 equiv). After the solution was stirred at room temperature for 2.0 h and then worked up, the residue was purified by use of column chromatography (5.0% methanol in dichloromethane as the eluent) to give 3a (63.4 mg, 0.246 mmol) in 86% yield as a white solid: mp (recrystallized from EtOH) 252.0–252.8 °C; 1H-NMR (CDCl3, 400 MHz) δ 7.58 (s, 1H, O=C–C=CH), 7.39 (s, 2H, 2 × NCH), 7.35–7.29 (m, 2H, 2 × ArH), 7.14–7.10 (m, 2H, 2 × ArH), 4.33 (s, 2H, SCH2); 13C-NMR (pyridine-d5, 100 MHz) δ 160.77 (C=O), 153.77, 140.38, 143.12, 139.37, 131.37, 128.18, 126.19, 124.58, 119.72, 116.42, 34.86 (SCH2); IR (KBr) 3307 (br, NH), 1713 (s, C=O), 1616 (m), 1587 (m), 1122 (m) cm−1; MS (FAB+) m/z 259 (MH+, 27), 154 (100), 137 (57), 107 (24), 89 (24). HRMS m/z calcd for C13H10N2O2S: 258.0463, found: 258.0462.

4.2.2. 2-[(6′-Fluorocoumarin-3′-yl)methylthio]imidazole (3b)

The standard procedure was followed by use of 1H-imidazole-2-thiol (1a, 29.1 mg, 0.291 mmol, 1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)-6-fluorocoumarin (2b, 74.2 mg, 0.349 mmol, 1.2 equiv). After the solution was stirred at room temperature for 2.0 h and then worked up, the residue was purified by use of column chromatography (5.0% methanol in dichloromethane as the eluent) to give 3b (59.9 mg, 0.218 mmol) in 75% yield as a white solid: mp (recrystallized from EtOH) 258.6–259.4 °C; 1H-NMR (DMSO-d6, 400 MHz) δ 7.58 (s, 1H, O=C–C=CH), 7.51–7.43 (m, 3H, 3 × ArH), 7.13 (s, 1H, 1 × NCH), 6.95 (s, 1H, 1 × NCH), 3.99 (s, 2H, SCH2); 13C-NMR (pyridine-d5, 100 MHz) δ 160.45 (C=O), 160.01, 157.61, 139.36, 127.33, 125.10, 120.56, 118.62, 118.37, 118.14, 113.54, 113.30, 34.71 (SCH2); IR (KBr) 3306 (br, NH), 1713 (s, C=O), 1619 (m), 1504 (m), 1188 (m) cm−1; MS (FAB+) m/z 277 (MH+, 19), 157 (31), 137 (22), 107 (9), 79 (100), 78 (23). HRMS m/z calcd for C13H9N2O2FS: 276.0369, found: 276.0368.

4.2.3. 2-[(6′-Chlorocoumarin-3′-yl)methylthio]imidazole (3c)

The standard procedure was followed by use of 1H-imidazole-2-thiol (1a, 25.6 mg, 0.256 mmol, 1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)-6-chlorocoumarin (2c, 70.3 mg, 0.307 mmol, 1.2 equiv). After the solution was stirred at room temperature for 2.0 h and then worked up, the residue was purified by use of column chromatography (5.0% methanol in dichloromethane as the eluent) to give 3c (48.6 mg, 0.166 mmol) in 65% yield as a white solid: mp (recrystallized from EtOH) 266.2–270.0 °C; 1H-NMR (DMSO-d6, 400 MHz) δ 7.73 (s, 1H, ArH), 7.60 (d, 1H, J = 8.8 Hz, ArH), 7.57 (s, 1H, O=C—C=CH), 7.43 (d, 1H, J = 8.8 Hz, ArH), 7.13 (s, 1H, NCH), 6.96 (s, 1H, NCH), 3.98 (s, 2H, SCH2); 13C-NMR (pridine-d5, 100 MHz) δ 160.26 (C=O), 152.08, 139.16, 139.08, 131.06, 129.28, 127.42, 125.11, 122.97, 120.85, 118.05, 34.64 (SCH2); IR (KBr) 3309 (br, NH), 1714 (s, C=O), 1615 (m), 1504 (m), 1189 (m) cm−1; MS (FAB+) m/z 293 (MH+, 14), 154 (100), 137 (57), 107 (22), 89 (23), 77 (20). HRMS m/z calcd for C13H9N2O2ClS: 292.0073, found: 292.0074.

4.2.4. 2-[(6′-Bromocoumarin-3′-yl)methylthio]imidazole (3d)

The standard procedure was followed by use of 1H-imidazole-2-thiol (1a, 28.8 mg, 0.288 mmol, 1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)-6-bromocoumarin (2d, 94.5 mg, 0.345 mmol, 1.2 equiv). After the solution was stirred at room temperature for 2.0 h and then worked up, the residue was purified by use of column chromatography (5.0% methanol in dichloromethane as the eluent) to give 3d (71.8 mg, 0.213 mmol) in 74% yield as a white solid: mp (recrystallized from EtOH) 276.8–277.4 °C; 1H-NMR (CDCl3, 400 MHz) δ7.84 (d, J = 2.4 Hz, 1H, ArH), 7.71 (dd, J = 8.8, 2.4 Hz, 1H, ArH), 7.56 (s, 1H, O=C–C=CH), 7.37 (d, J = 8.8 Hz, 1H, ArH), 7.04 (s, 2H, 2 × NCH), 3.98 (s, 2H, SCH2); 13C-NMR (pyridine-d5/DMSO-d6, 100 MHz) δ 160.23 (C=O), 152.09, 139.40, 137.95, 134.26, 130.28, 126.27, 126.07, 120.93, 118.52, 116.71, 34.38 (SCH2); IR (KBr) 3307 (br, NH), 1714 (s, C=O), 1620 (m), 1504 (m), 1189 (m), 1123 (m) cm−1; MS (FAB+) m/z 337 (MH+, 18), 154 (100), 137 (55), 107 (24), 89 (29), 77 (21). HRMS m/z calcd for C13H9N2O2BrS: 335.9568, found: 335.9649.

4.2.5. 2-[(8′-Methoxycoumarin-3′-yl)methylthio]imidazole (3e)

The standard procedure was followed by use of 1H-imidazole-2-thiol (1a, 28.7 mg, 0.287 mmol, 1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)-8-methoxycoumarin (2e, 76.6 mg, 0.344 mmol, 1.2 equiv). After the solution was stirred at room temperature for 2.0 h and then worked up, the residue was purified by use of column chromatography (5.0% methanol in dichloromethane as the eluent) to give 3e (66.3 mg, 0.229 mmol) in 80% yield as a white solid: mp (recrystallized from EtOH) 269.8–270.6 °C; 1H-NMR (DMSO-d6, 400 MHz) δ 7.55 (s, 1H, O=C–C=CH), 7.31–7.21 (m, 2H, ArH), 7.10–7.09 (m, 1H, ArH), 7.08 (s, 1H, NCH), 6.97 (s, 1H, NCH), 3.98 (s, 2H, SCH2), 3.89 (s 3H, OCH3); 13C-NMR (pyridine-d5/DMSO-d6, 100 MHz) δ 160.45 (C=O), 146.80, 142.83, 140.69, 138.74, 125.60, 124.54, 122.96, 119.91, 119.71, 119.36, 113.62, 55.93 (OCH3), 34.52 (SCH2); IR (KBr) 3307 (br, NH), 1713 (s, C=O), 1615 (m), 1504 (m), 1189 (m) cm−1; MS (FAB+) m/z 289 (MH+, 15), 154 (100), 137 (52), 107 (28), 89 (23), 77 (24). HRMS m/z calcd for C14H12N2O3S: 288.0569, found: 288.0570.

4.2.6. 1-Methyl-2-[(coumarin-3′-yl)methylthio]imidazole (3f)

The standard procedure was followed by use of 1-methyl-imidazole-2-thiol (1b, 33.2 mg, 0.291 mmol, 1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)coumarin (2a, 85.1 mg, 0.437 mmol, 1.5 equiv). After the solution was stirred at room temperature for 2.0 h and then worked up, the residue was purified by use of column chromatography (40% dichloromethane in EtOAc as the eluent) to give 3f (54.9 mg, 0.201 mmol) in 69% yield as a white solid: mp (recrystallized from EtOH) 244.2–244.8 °C; 1H-NMR (CDCl3, 400 MHz) δ 7.53 (s, 1H, O=C–C=CH), 7.45 (t, J = 7.2 Hz, 1H, ArH), 7.34 (s, J = 7.8 Hz, 1H, ArH), 7.28–7.19 (m, 2H, 2 × ArH), 7.05 (s, 1H, NCH), 6.85 (s, 1H, NCH), 4.12 (s, 2H, SCH2), 3.47 (s, 3H, NCH3); 13C-NMR (CDCl3, 100 MHz) δ 160.82 (C=O), 153.45, 140.55, 131.3129.47, 127.77, 125.01, 124.45, 122.57, 119.15, 116.67, 116.47, 33.92 (SCH2), 33.20 (CH3); IR (KBr) 1713 (s, C=O), 1616 (m), 1519 (m), 1170 (m) cm−1; MS (FAB+) m/z 272 (M+, 30), 154 (100), 136 (77), 89 (33), 77 (20), 55 (60); HRMS m/z calcd for C14H12N2O2S: 272.0619, found: 272.0620.

4.2.7. 1-Methyl-2-[(6′-chlorocoumarin-3′-yl)methylthio]imidazole (3g)

The standard procedure was followed by use of 1-methyl-imidazole-2-thiol (1b, 36.2 mg, 0.317 mmol, 1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)-6-chlorocoumarin (2c, 109 mg, 0.476 mmol, 1.5 equiv). After the solution was stirred at room temperature for 2.0 h and then worked up, the residue was purified by use of column chromatography (40% dichloromethane in EtOAc as the eluent) to give 3g (70.5 mg, 0.231 mmol) in 73% yield as a white solid: mp (recrystallized from EtOH) 256.2–257.2 °C; 1H-NMR (CDCl3, 400 MHz) δ 7.51 (s, 1H, O=C–C=CH), 7.40 (d, J = 8.8 Hz, 1H, ArH), 7.34 (s, 1H, ArH), 7.22 (d, J = 8.8 Hz, 1H, ArH), 7.06 (s, 1H, NCH), 6.87 (s, 1H, NCH), 4.12 (s, 2H, SCH2), 3.49 (s, 3H, NCH3); 13C-NMR (CDCl3, 100 MHz) δ 160.27 (C=O), 151.80, 140.40, 139.27, 131.23, 129.73, 129.49, 126.98, 126.38, 122.66, 120.22, 117.92, 33.56 (SCH2), 33.20 (CH3); IR (KBr) 1705 (s, C=O), 1615 (m), 1518 (m), 1233 (m) cm−1; MS (FAB+) m/z 307 (MH+, 100), 154 (66), 136 (59), 77 (30), 55 (35), 77 (20); HRMS m/z calcd for C14H11N2O2ClS: 306.0230, found: 306.0233.

4.2.8. 1-(2′,3′,5′-Tri-O-acetyl-β-d-ribofuranos-1′-yl)imidazole-2-thiol (5)

To a solution of 1H-imidazole-2-thiol (1a, 375 mg, 3.74 mmol, 1.0 equiv) in dry acetonitrile (30 mL) was added BTSA (1.20 mL, 4.91 mmol, 1.3 equiv) under nitrogen atmosphere according to the Vorbrüggen procedure [43]. After the solution was stirred at 60 °C for 30 min, 1,2,3,5-tetra-O-acetyl-β-d-ribofuranose (4, 1.25 g, 3.93 mmol, 1.1 equiv) and Me3SiOTf (0.711 mL, 3.93 mmol, 1.1 equiv) were added in sequence. The reaction mixture was heated to 80 °C and stirred for 18 h. Excess solvent was removed under reduced pressure, and the residue was treated with 20% aqueous NaHCO3 solution (30 mL). The aqueous layer was extracted with ethyl acetate (3 × 25 mL). The combined organic layers were washed with brine (30 mL), dried over MgSO4 (s), filtered, and concentrated under reduced pressure to afford a residue, which was purified by use of column chromatography (20% hexanes in EtOAc as the eluent) to give 5 (698.4 mg, 1.945 mmol) in 52% yield. 1H-NMR (CDCl3, 400 MHz) δ 6.90 (s, 1H, NCH), 6.72 (s, 1H, NCH), 6.47 (s, 1H, H-1″), 5.44 (t, J = 5.2 Hz, 1H, H-2″), 5.31 (t, J = 5.2 Hz, 1H, H-3″), 4.38–4.36 (m, 1H, H-4″), 4.33–4.28 (m, 2H, 2 × H-5″), 2.13 (s, 3H, CO2CH3), 2.11 (s, 3H, CO2CH3), 2.09 (s, 3H, CO2CH3). These data are consistent with those reported [48].

4.2.9. 1-β-d-Ribofuranosyl-imidazole-2-thiol (6)

To a solution containing 5 (82.6 mg, 0.230 mmol, 1.0 equiv) in methanol (10 mL) was added potassium carbonate (31.9 mg, 0.231 mmol, 1.0 equiv) at room temperature. After the solution was stirred at 0 °C for 12 h, it was concentrated under reduced pressure. To the residue was added saturated aqueous NH4Cl (20 mL), which was extracted with CHCl3 (3 × 20 mL). The combined organic layers were washed with brine (20 mL), dried over MgSO4 (s), filtered, and concentrated under reduced pressure. The residue was then purified by use of column chromatography (10% MeOH in EtOAc as the eluent) to give 6 (49.1 mg, 0.212 mmol) in 92% yield. 1H-NMR (DMSO-d6, 400 MHz) δ 7.29 (s, 1H, NCH), 6.91 (s, 1H, NCH), 6.02 (s, 1H, H-1″), 5.27 (d, J = 6.6 Hz, 1H, OH), 5.03 (d, J = 4.0 Hz, 1H, OH), 4.98 (t, J = 5.2 Hz, 1H, OH), 4.07–4.04 (m, 1H, H-2″), 4.03–3.99 (m, 1H, H-3″), 3.83–3.81 (m, 1H, H-4″), 3.63–3.53 (m, 2H, 2 × H-5″). These data are consistent with those reported [48].

4.2.10. 1-(β-d-Ribofuranos-1″-yl)-2-[(coumarin-3′-yl)methylthio]imidazole (7a)

The standard procedure was followed by use of 1-β-d-ribofuranosyl-imidazole-2-thiol (6, 43.1 mg, 0.186 mmol, 1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)coumarin (2a, 43.4 mg, 0.223 mmol, 1.2 equiv). After the solution was stirred at room temperature for 2.0 h and then worked up, the residue was purified by use of column chromatography (10% MeOH in dichloromethane as the eluent) to give 7a (53.7 mg, 0.165 mmol) in 74% yield as a white solid: mp (recrystallized from EtOH) 164.6–165.4 °C; 1H-NMR (DMSO-d6, 400 MHz) δ 7.66 (s, 1H, O=C–C=CH), 7.58–7.54 (m, 2H, 2 × ArH), 7.49 (s, 1H, NCH), 7.38 (d, J = 8.4 Hz, 1H, ArH), 7.30 (t, J = 7.6 Hz, 1H, ArH), 6.99 (s, 1H, NCH), 5.67 (d, J = 7.2 Hz, 1H, H-1″), 5.37 (d, J = 6.4 Hz, 1H, OH), 5.17 (d, J = 4.4 Hz, 1H, OH), 4.93 (t, J = 5.2 Hz, 1H, OH), 4.16–4.11 (m, 1H, H-2″), 4.04 (s, 2H, SCH2), 3.99–3.98 (m, 1H, H-3″), 3.78–3.76 (m, 1H, H-4″), 3.43–3.39 (m, 2H, 2 × H-5″); 13C-NMR (DMSO-d6, 100 MHz) δ 160.03 (C=O), 151.94, 140.67, 139.65, 131.57, 129.62, 128.20, 124.59, 124.44, 119.54, 118.97, 116.00, 88.13, 85.58, 75.10, 70.55, 61.36, 34.27 (SCH2); IR (KBr) 3387 (br, OH), 1698 (s, C=O), 1609 (m), 1457 (m), 1111 (m) cm−1; MS (FAB+) m/z 391 (MH+, 66), 154 (100), 137 (54), 77 (33); HRMS m/z calcd for C18H18N2O6S: 390.0886, found: 390.0891.

4.2.11. 1-(β-d-Ribofuranos-1″-yl)-2-[(6′-fluorocoumarin-3′-yl)methylthio]imidazole (7b)

The standard procedure was followed by use of 1-β-d-ribofuranosyl-imidazole-2-thiol (6, 44.9 mg, 0.193 mmol, 1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)-6-fluorocoumarin (2b, 49.3 mg, 0.232 mmol, 1.2 equiv). After the solution was stirred at room temperature for 2.0 h and then worked up, the residue was purified by use of column chromatography (10% MeOH in dichloromethane as the eluent) to give 7b (62.9 mg, 0.154 mmol) in 80% yield as a white solid: mp (recrystallized from EtOH) 171.2–172.4 °C; 1H-NMR (DMSO-d6, 400 MHz) δ 7.62 (s, 1H, O=C–C=CH), 7.50 (s, 1H, ArH), 7.47–7.42 (m, 3H, 2 × ArH + NCH), 7.00 (s, 1H, NCH), 5.65 (d, J = 6.4 Hz, 1H, H-1″), 5.36 (d, J = 6.8 Hz, 1H, OH), 5.18 (d, J = 7.6 Hz, 1H, OH), 4.94 (t, J = 5.2 Hz, 1H, OH), 4.16–4.11 (m, 1H, H-2″), 4.03 (s, 2H, SCH2), 4.00–3.97 (m, 1H, H-3″), 3.77–3.74 (m, 1H, H-4″), 3.42–3.38 (m, 2H, 2 × H-5″); 13C-NMR (CDCl3, 100 MHz) δ 159.73 (C=O), 149.28, 139.60, 139.51, 129.64, 125.67, 119.97, 119.52, 118.78, 118.54, 117.96, 113.49, 88.08, 85.54, 75.01, 70.49, 61.32, 34.22 (SCH2); IR (KBr) 3388 (br, OH), 1694 (s, C=O), 1580 (m), 1489 (m), 1265 (m), 1078 (m) cm−1; MS (FAB+) m/z 409 (MH+, 54), 154 (100), 137 (57), 77 (31), 55 (66); HRMS m/z calcd for C18H17N2O6FS: 408.0791, found: 408.0794.

4.2.12. 1-(β-d-Ribofuranos-1″-yl)-2-[(6′-chlorocoumarin-3′-yl)methylthio]imidazole (7c)

The standard procedure was followed by use of 1-β-d-ribofuranosyl-imidazole-2-thiol (6, 44.6 mg, 0.192 mmol, 1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)-6-chlorocoumarin (2c, 52.8 mg, 0.231 mmol, 1.2 equiv). After the solution was stirred at room temperature for 2.0 h and then worked up, the residue was purified by use of column chromatography (10% MeOH in dichloromethane as the eluent) to give 7c (61.2 mg, 0.144 mmol) in 75% yield as a white solid: mp (recrystallized from EtOH) 178.8–179.6 °C; 1H-NMR (DMSO-d6, 400 MHz) δ 7.69 (s, 1H, O=C–C=CH), 7.60 (s, 1H, ArH), 7.59–7.57 (m, 2H, 2 × ArH), 7.49 (s, 1H, NCH), 7.41 (d, J = 8.8 Hz, 1H, ArH), 7.00 (s, 1H, NCH), 5.65 (d, J = 6.4 Hz, 1H, H-1″), 5.34 (d, J = 6.4 Hz, 1H, OH), 5.16 (d, J = 4.8 Hz, 1H, OH), 4.92 (t, J = 5.2 Hz, 1H, OH), 4.15–4.11 (m, 1H, H-2″), 4.02 (s, 2H, SCH2), 4.00–3.97 (m, 1H, H-3″), 3.77–3.74 (m, 1H, H-4″), 3.41–3.38 (m, 2H, 2 × H-5″); 13C-NMR (CDCl3, 100 MHz) δ 159.53 (C=O), 151.54, 139.44, 139.31, 131.05, 129.67, 128.27, 127.17, 125.75, 120.38, 119.54, 117.98, 88.07, 85.55, 75.01, 70.50, 61.31, 34.31 (SCH2); IR (KBr) 3399 (br, OH), 1695 (s, C=O), 1615 (m), 1580 (m), 1441 (m), 1265 (m), 1173 (m) cm−1; MS (FAB+) m/z 425 (MH+, 55), 154 (100), 137 (53), 77 (35), 55 (61); HRMS m/z calcd for C18H17N2O6ClS: 424.0496, found: 424.0580.

4.2.13. 1-(β-d-Ribofuranos-1″-yl)-2-[(6′-bromocoumarin-3′-yl)methylthio]imidazole (7d)

The standard procedure was followed by use of 1-β-d-ribofuranosyl-imidazole-2-thiol (6, 47.2 mg, 0.203 mmol, 1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)-6-bromocoumarin (2d, 66.7 mg, 0.244 mmol, 1.2 equiv). After the solution was stirred at room temperature for 2.0 h and then worked up, the residue was purified by use of column chromatography (10% MeOH in dichloromethane as the eluent) to give 7d (79.8 mg, 0.171 mmol) in 84% yield as a white solid: mp (recrystallized from EtOH) 188.8–189.4 °C; 1H-NMR (DMSO-d6, 400 MHz) δ 7.82 (s, 1H, O=C–C=CH), 7.72–7.69 (m, 1H, ArH), 7.60 (s, 1H, ArH), 7.50 (s, 1H, NCH), 7.36 (d, J = 8.8 Hz, 1H, ArH), 7.01 (s, 1H, NCH), 5.65 (d, J = 7.2 Hz, 1H, H-1″), 5.36 (d, J = 6.8 Hz, 1H, OH), 5.17 (d, J = 4.4 Hz, 1H, OH), 4.93 (t, J = 5.2 Hz, 1H, OH), 4.16–4.11 (m, 1H, H-2″), 4.02 (s, 2H, SCH2), 4.00–3.97 (m, 1H, H-3″), 3.76–3.74 (m, 1H, H-4″), 3.41–3.38 (m, 2H, 2 × H-5″); 13C-NMR (CDCl3, 100 MHz) δ 159.46 (C=O), 151.95, 139.39, 139.23, 133.82, 130.13, 129.63, 125.68, 120.86, 119.56, 118.25, 116.09, 88.07, 85.56, 75.02, 70.50, 61.30, 34.33 (SCH2); IR (KBr) 3400 (br, OH), 1693 (s, C=O), 1599 (m), 1479 (m), 1399 (m), 1263 (m), 1172 (m) cm−1; MS (FAB+) m/z 469 (MH+, 45), 154 (100), 137 (55), 77 (32), 55 (60); HRMS m/z calcd for C18H17N2O6BrS: 467.9991, found: 468.0072.

4.2.14. 1-(β-d-Ribofuranos-1″-yl)-2-[(8′-methoxycoumarin-3′-yl)methylthio]imidazole (7e)

The standard procedure was followed by use of 1-β-d-ribofuranosyl-imidazole-2-thiol (6, 46.8 mg, 0.201 mmol, 1.0 equiv), aqueous ammonium hydroxide (0.25 mL), and 3-(chloromethyl)-8-methoxycoumarin (2e, 53.8 mg, 0.241 mmol, 1.2 equiv). After the solution was stirred at room temperature for 2.0 h and then worked up, the residue was purified by use of column chromatography (10% MeOH in dichloromethane as the eluent) to give 7e (61.2 mg, 0.145 mmol) in 72% yield as a white solid: mp (recrystallized from EtOH) 169.6–170.4 °C; 1H-NMR (DMSO-d6, 400 MHz) δ 7.63 (s, 1H, O=C–C=CH), 7.49 (s, 1H, NCH), 7.25–7.20 (m, 2H, 2 × ArH), 7.10–7.08 (m, 1H, ArH), 6.99 (s, 1H, NCH), 5.66 (d, J = 6.0 Hz, 1H, H-1″), 5.38 (d, J = 6.8 Hz, 1H, OH), 5.18 (d, J = 4.4 Hz, 1H, OH), 4.94 (t, J = 5.2 Hz, 1H, OH), 4.16–4.11 (m, 1H, H-2″), 4.07 (s, 2H, SCH2), 4.03–3.97 (m, 1H, H-3″), 3.88 (s, 3H, OCH3), 3.79–3.76 (m, 1H, H-4″), 3.43–3.40 (m, 2H, 2 × H-5″); 13C-NMR (DMSO-d6, 100 MHz) δ 159.71 (C=O), 146.33, 142.24, 140.85, 139.58, 129.57, 124.60, 124.50, 119.49, 119.36, 113.86, 88.10, 85.54, 75.05, 70.49, 61.33, 56.08 (OCH3), 34.14 (SCH2); IR (KBr) 3403 (br, OH), 1695 (s, C=O), 1579 (m), 1402 (m), 1265 (m), 1102 (m), 1078 (m) cm−1; MS (FAB+) m/z 421 (MH+, 15), 154 (100), 137 (30), 77 (66), 55 (67); HRMS m/z calcd for C19H20N2O7S: 420.0991, found: 420.0987.

4.2.15. 8-[(Coumarin-3′-yl)methylthio]inosine (9a)

The standard procedure was followed by use of 8 (48.7 mg, 0.162 mmol, 1.0 equiv), water (2.5 mL), acetonitrile (1.5 mL), aqueous ammonium hydroxide (0.15 mL), and 3-(chloromethyl)coumarin (2a, 37.8 mg, 0.194 mmol, 1.2 equiv). It was stirred at room temperature for 30 min and then worked up. The residue was purified by use of column chromatography (10% methanol in CH2Cl2 as the eluent) to give 9a (52.4 mg, 0.114 mmol) in 70% yield as a white solid: mp (recrystallized from dichloromethane/methanol) 160.9–162.5 °C; 1H-NMR (DMSO-d6, 400 MHz) δ 8.06 (s, 1H, H-2), 8.02 (s, 1H, CH=C–COO), 7.65–7.57 (m, 2H, 2 × ArH), 7.41 (d, J = 8.4 Hz, 1H, ArH), 7.33 (dd, J = 7.6, 7.2 Hz, 1H, ArH), 5.76 (d, J = 6.4 Hz, 1H, H-1″), 5.41 (d, J = 5.6 Hz, 1H, OH), 5.19 (d, J = 3.6 Hz, 1H, OH), 5.01–4.99 (br, 1H, OH), 4.89–4.85 (m, 1H, H-2″), 4.39 (d, J = 14.2 Hz, 1H, SCH), 4.35 (d, J = 14.2 Hz, 1H, SCH), 4.12–4.09 (m, 1H, H-3″), 3.88–3.85 (m, 1H, H-4″), 3.63–3.57 (m, 1H, H-5″), 3.50–3.44 (m, 1H, H-5″); 13C-NMR (DMSO-d6, 100 MHz) δ 160.07 (C=O), 155.37 (C=O), 152.89, 149.57, 146.63, 145.28, 141.20, 131.76, 128.37, 124.90, 124.60, 123.84, 118.74, 116.10, 88.74, 86.06, 71.16, 70.50, 61.81, 32.04 (SCH2); IR (ATR) 3359 (br, OH + NH), 1707 (s, C=O), 1678 (s, C=O), 1583 (m), 1189 (m), 1051 (s) cm−1; MS (FAB+) m/z 459 (MH+, 2), 327 (4), 221 (13), 147 (13), 55 (100); HRMS (FAB) calcd for (C20H18N4O7S + H)+: 459.0974, found: 459.0984.

4.2.16. 8-[(6′-Fluorocoumarin-3′-yl)methylthio]inosine (9b)

The standard procedure was followed by use of 8 (56.7 mg, 0.189 mmol, 1.0 equiv), water (2.5 mL), acetonitrile (1.5 mL), aqueous ammonium hydroxide (0.15 mL), and 3-(chloromethyl)-6-fluorocoumarin (2b, 48.2 mg, 0.227 mmol, 1.2 equiv). It was stirred at room temperature for 30 min and then worked up. The residue was purified by use of column chromatography (10% methanol in CH2Cl2 as the eluent) to give 9b (74.4 mg, 0.156 mmol) in 83% yield as a white solid: mp (recrystallized from dichloromethane/methanol) 168.3–169.1 °C; 1H-NMR (DMSO-d6, 400 MHz) δ 12.50–12.42 (br, 1H, NH), 8.03 (s, 1H, H-2), 8.01 (s, 1H, CH=C–COO), 7.56–7.54 (m, 1H, ArH), 7.48–7.46 (m, 2H, 2 × ArH), 5.76 (d, J = 6.4 Hz, 1H, H-1″), 5.43 (d, J = 6.0 Hz, 1H, OH), 5.23 (d, J = 4.4 Hz, 1H, OH), 5.01–4.99 (br, 1H, OH), 4.89–4.85 (m, 1H, H-2″), 4.39 (d, J = 14.2 Hz, 1H, SCH), 4.34 (d, J = 14.2 Hz, 1H, SCH), 4.12–4.08 (m, 1H, H-3″), 3.88–3.84 (m, 1H, H-4″), 3.62–3.57 (m, 1H, H-5″), 3.50–3.44 (m, 1H, H-5″); 13C-NMR (DMSO-d6, 100 MHz) δ 159.86 (C=O), 158.08 (d, C=O), 155.40, 149.60, 149.28, 146.51, 145.35, 140.09, 125.18, 124.99, 119.75 (d), 118.95 (d), 118.05 (d), 113.56 (d), 88.79, 86.15, 71.29, 70.45, 61.83, 32.09 (SCH2); IR (ATR) 3359 (br, OH + NH), 1706 (s, C=O), 1676 (s, C=O), 1583 (m), 1452 (m), 1188 (m), 1061 (s) cm−1; MS (FAB+) m/z 477 (MH+, 25), 345 (65), 289 (45), 154 (100), 120 (49); HRMS (FAB) calcd for (C20H17FN4O7S + H)+: 477.0880, found: 477.0877.

4.2.17. 8-[(6′-Bromocoumarin-3′-yl)methylthio]inosine (9d)

The standard procedure was followed by use of 8 (45.8 mg, 0.153 mmol, 1.0 equiv), water (2.5 mL), acetonitrile (1.5 mL), aqueous ammonium hydroxide (0.15 mL), and 6-bromo-3-(chloromethyl)coumarin (2d, 50.2 mg, 0.184 mmol, 1.2 equiv). It was stirred at room temperature for 20 min and then worked up. The residue was purified by use of column chromatography (10% methanol in CH2Cl2 as the eluent) to give 9d (66.4 mg, 0.126 mmol) in 80% yield as a white solid: mp (recrystallized from dichloromethane/methanol) 169.1–170.5 °C; 1H-NMR (DMSO-d6, 400 MHz) δ 11.95–11.92 (br, 1H, NH), 8.04 (s, 1H, H-2), 8.00 (s, 1H, CH=C–COO), 7.90 (d, J = 2.4 Hz, 1H, ArH), 7.73 (dd, J = 8.8, 2.4 Hz, 1H, ArH), 7.38 (d, J = 8.8 Hz, 1H, ArH), 5.76 (d, J = 6.8 Hz, 1H, H-1″), 5.42–5.40 (br, 1H, OH), 5.22–5.20 (br, 1H, OH), 4.96–4.94 (br, 1H, OH), 4.89–4.86 (m, 1H, H-2″), 4.38 (d, J = 14.4 Hz, 1H, SCH), 4.34 (d, J = 14.4 Hz, 1H, SCH), 4.12–4.09 (m, 1H, H-3″), 3.88–3.85 (m, 1H, H-4″), 3.62–3.59 (m, 1H, H-5″), 3.50–3.45 (m, 1H, H-5″); 13C-NMR (DMSO-d6, 100 MHz) δ 159.61 (C=O), 155.36 (C=O), 151.93, 149.58, 146.45, 145.32, 139.72, 134.08, 130.32, 125.19, 124.98, 120.66, 118.36, 116.21, 88.79, 86.15, 71.29, 70.45, 61.83, 32.09 (SCH2); IR (ATR) 3356 (br, OH + NH), 1708 (s, C=O), 1678 (s, C=O), 1585 (m), 1188 (m), 1022 (s) cm−1; MS (FAB+) m/z 537 (MH+, 2), 427 (13), 307 (19), 185 (26), 154 (100); HRMS (FAB) calcd for (C20H17BrN4O7S + H)+: 537.0080, found: 537.0077.

4.2.18. 8-[(8′-Methoxycoumarin-3′-yl)methylthio]inosine (9e)

The standard procedure was followed by use of 8 (35.8 mg, 0.119 mmol, 1.0 equiv), water (2.5 mL), acetonitrile (1.5 mL), aqueous ammonium hydroxide (0.15 mL), and 3-chloromethyl-8-methoxycoumarin (2e, 41.9 mg, 0.201 mmol, 1.2 equiv). It was stirred at room temperature for 30 min and then worked up. The residue was purified by use of column chromatography (10% methanol in CH2Cl2 as the eluent) to give 9e (46.7 mg, 95.6 μmol) in 80% yield as a white solid: mp (recrystallized from dichloromethane/methanol) 162.3–164.1 °C; 1H-NMR (DMSO-d6, 400 MHz) δ 12.52–12.39 (br, 1H, NH), 8.04 (s, 1H, H-2), 8.03 (s, 1H, CH=C–COO), 7.28–7.23 (m, 2H, 2 × ArH), 7.18–7.16 (m, 1H, ArH), 5.75 (d, J = 6.4 Hz, 1H, H-1″), 5.45–5.41 (br, 1H, OH), 5.23–5.21 (br, 1H, OH), 4.96 (dd, J = 6.0, 5.6 Hz, 1H, OH), 4.88–4.85 (m, 1H, H-2″), 4.39 (d, J = 14.0 Hz, 1H, SCH), 4.34 (d, J = 14.0 Hz, 1H, SCH), 4.13–4.09 (m, 1H, H-3″), 3.89 (s, 3H, OCH3), 3.87–3.85 (m, 1H, H-4″), 3.62–3.59 (m, 1H, H-5″), 3.49–3.46 (m, 1H, H-5″); 13C-NMR (DMSO-d6, 100 MHz) δ 159.83 (C=O), 155.39 (C=O), 149.60, 146.69, 146.39, 145.31, 142.24, 141.15, 124.96, 124.67, 124.03, 119.49, 119.32, 114.13, 88.76, 86.15, 71.28, 70.46, 61.83, 56.10 (OCH3), 32.01 (SCH2); IR (ATR) 3354 (br, OH + NH), 1708 (s, C=O), 1692 (s, C=O), 1583 (m), 1189 (m), 1060 (s) cm−1; MS (ESI) m/z 488 (M+); HRMS (ESI) calcd for (C21H20N4O8S)+: 488.1002, found: 488.1011.

4.2.19. 8-[(6′-Methylcoumarin-3′-yl)methylthio]inosine (9f)

The standard procedure was followed by use of 8 (50.2 mg, 0.167 mmol, 1.0 equiv), water (2.5 mL), acetonitrile (1.5 mL), aqueous ammonium hydroxide (0.15 mL), and 3-chloromethyl-6-methylcoumarin (2f, 41.9 mg, 0.201 mmol, 1.2 equiv). It was stirred at room temperature for 15 min and then worked up. The residue was purified by use of column chromatography (10% methanol in CH2Cl2 as the eluent) to give 9f (64.6 mg, 0.137 mmol) in 82% yield as a white solid: mp (recrystallized from dichloromethane/methanol) 156.8–158.4 °C; 1H-NMR (DMSO-d6, 400 MHz) δ 12.48–12.38 (br, 1H, NH), 8.03 (s, 1H, H-2), 8.01 (s, 1H, CH=C–COO), 7.41–7.38 (m, 2H, 2 × ArH), 7.30 (d, J = 8.4 Hz, 1H, ArH), 5.75 (d, J = 6.4 Hz, 1H, H-1″), 5.43 (d, J = 5.2 Hz, 1H, OH), 5.22 (d, J = 2.4 Hz, 1H, OH), 4.95 (dd, J = 6.0, 5.6 Hz, 1H, OH), 4.88–4.86 (m, 1H, H-2″), 4.38 (d, J = 14.0 Hz, 1H, SCH), 4.34 (d, J = 14.0 Hz, 1H, SCH), 4.12–4.09 (m, 1H, H-3″), 3.89–3.85 (m, 1H, H-4″), 3.64–3.58 (m, 1H, H-5″), 3.51–3.48 (m, 1H, H-5″), 2.32 (s, 3H, CH3); 13C-NMR (DMSO-d6, 100 MHz) δ 160.26 (C=O), 155.37 (C=O), 151.07, 149.62, 146.77, 145.27, 141.16, 134.00, 132.66, 127.95, 124.95, 123.78, 118.50, 115.86, 88.76, 86.15, 71.29, 70.45, 61.85, 32.00 (SCH2), 20.17 (CH3); IR (ATR) 3345 (br, OH + NH), 1707 (s, C=O), 1692 (s, C=O), 1583 (m), 1188 (m), 1023 (s) cm−1; MS (FAB+) m/z 473 (MH+, 1), 341 (10), 185 (16), 109 (30), 55 (100); HRMS (FAB) calcd for (C21H20N4O7S)+: 472.1053, found: 472.1060.

4.2.20. 8-[(6′-Fluorocoumarin-3′-yl)methylthio]guanosine (11b)

The standard procedure was followed by use of 10 (65.2 mg, 0.207 mmol, 1.0 equiv), water (5.0 mL), acetonitrile (3.0 mL), aqueous ammonium hydroxide (0.25 mL), and 3-chloromethyl-6-fluorocoumarin (2b, 52.8 mg, 0.248 mmol, 1.2 equiv). It was stirred at room temperature for 15 min and then worked up. The residue was purified by use of column chromatography (15% methanol in CH2Cl2 as the eluent) to give 11b (90.2 mg, 0.183 mmol) in 89% yield as a white solid: mp (recrystallized from dichloromethane/methanol) 184.9–186.2 °C; 1H-NMR (DMSO-d6, 400 MHz) δ 10.70–10.66 (br, 1H, NH), 7.90 (s, 1H, CH=C–COO), 7.53–7.42 (m, 3H, 3 × ArH), 6.41 (s, 2H, NH2), 5.70 (d, J = 6.8 Hz, 1H, H-1″), 5.35 (d, J = 6.0 Hz, 1H, OH), 5.07 (d, J = 4.8 Hz, 1H, OH), 4.94 (dd, J = 6.8, 5.2 Hz, 1H, OH), 4.89–4.85 (m, 1H, H-2″), 4.24 (d, J = 14.0 Hz, 1H, SCH), 4.19 (d, J = 14.0 Hz, 1H, SCH), 4.10–4.06 (m, 1H, H-3″), 3.80–3.76 (m, 1H, H-4″), 3.62–3.56 (m, 1H, H-5″), 3.49–3.43 (m, 1H, H-5″); 13C-NMR (DMSO-d6, 100 MHz) δ 159.83 (C=O), 158.07 (d, C=O), 155.60, 153.10, 152.47, 149.25, 141.48, 139.84, 125.44, 119.81 (d), 118.83 (d), 118.00 (d), 117.42, 113.47 (d), 88.27, 85.74, 70.53, 61.96, 32.77 (SCH2); IR (ATR) 3146 (br, OH + NH), 1723 (m, C=O), 1681 (s, C=O), 1626 (s), 1071(s) cm−1; MS (FAB+) m/z 492 (MH+, 35), 360 (62), 307 (98), 219 (23), 156 (100), 107 (100); HRMS (FAB) calcd for (C20H18FN5O7S + H)+: 492.0989, found: 492.0996.

4.2.21. 8-[(8′-Methoxycoumarin-3′-yl)methylthio]guanosine (11e)

The standard procedure was followed by use of 10 (63.7 mg, 0.202 mmol, 1.0 equiv), water (5.0 mL), acetonitrile (3.0 mL), aqueous ammonium hydroxide (0.25 mL), and 3-chloromethyl-8-methoxycoumarin (2e, 54.0 mg, 0.243 mmol, 1.2 equiv). It was stirred at room temperature for 1.0 h and then worked up. The residue was purified by use of column chromatography (10% methanol in CH2Cl2 as the eluent) to give 11e (84.3 mg, 0.167 mmol) in 83% yield as a white solid: mp (recrystallized from dichloromethane/methanol) 192.8–194.3 °C; 1H-NMR (DMSO-d6, 400 MHz) δ 10.68–10.64 (br, 1H, NH), 7.93 (s, 1H, CH=C–COO), 7.28–7.23 (m, 2H, 2 × ArH), 7.16–7.14 (m, 1H, ArH), 6.42 (s, 2H, NH2), 5.69 (d, J = 6.8 Hz, 1H, H-1″), 5.38 (d, J = 6.4 Hz, 1H, OH), 5.09 (d, J = 5.2 Hz, 1H, OH), 4.95 (dd, J = 6.0, 5.6 Hz, 1H, OH), 4.88–4.84 (m, 1H, H-2″), 4.24 (d, J = 13.8 Hz, 1H, SCH), 4.19 (d, J = 13.8 Hz, 1H, SCH), 4.09–4.05 (m, 1H, H-3″), 3.89 (s, 3H, OCH3), 3.80–3.77 (m, 1H, H-4″), 3.61–3.56 (m, 1H, H-5″), 3.49–3.43 (m, 1H, H-5″); 13C-NMR (DMSO-d6, 100 MHz) δ 159.87 (C=O), 155.68 (C=O), 153.14, 152.55, 146.41, 142.25, 141.73, 141.24, 124.66, 124.34, 119.47, 119.41, 117.38, 114.05, 88.26, 85.78, 70.53, 62.01, 56.16 (OCH3), 32.63 (SCH2); IR (ATR) 3142 (br, OH + NH), 1714 (m, C=O), 1682 (s, C=O), 1274 (m), 1092 (m) cm−1; MS (FAB+) m/z 503 (M+, 2), 372 (10), 232 (11), 154 (45), 79 (100); HRMS (FAB) calcd for (C21H21N5O8S)+: 503.1107, found: 503.1111.

4.2.22. 8-[(6′-Methylcoumarin-3′-yl)methylthio]guanosine (11f)

The standard procedure was followed by use of 10 (52.3 mg, 0.166 mmol, 1.0 equiv), water (5.0 mL), acetonitrile (3.0 mL), aqueous ammonium hydroxide (0.25 mL), and 3-chloromethyl-6-methylcoumarin (2f, 41.5 mg, 0.199 mmol, 1.2 equiv). It was stirred at room temperature for 30 min and then worked up. The residue was purified by use of column chromatography (15% methanol in CH2Cl2 as the eluent) to give 11f (59.6 mg, 0.122 mmol) in 74% yield as a white solid: 1H-NMR (DMSO-d6, 400 MHz) δ 10.74–10.70 (br, 1H, NH), 7.90 (s, 1H, CH=C–COO), 7.40–7.38 (m, 2H, 2 × ArH), 7.30 (d, J = 8.8 Hz, 1H, ArH), 6.46 (s, 2H, NH2), 5.69 (d, J = 6.4 Hz, 1H, H-1″), 5.38 (d, J = 6.4 Hz, 1H, OH), 5.09 (d, J = 4.8 Hz, 1H, OH), 4.95 (dd, J = 6.0, 6.0 Hz, 1H, OH), 4.88–4.84 (m, 1H, H-2″), 4.24 (d, J = 13.8 Hz, 1H, SCH), 4.19 (d, J = 13.8 Hz, 1H, SCH), 4.11–4.06 (m, 1H, H-3″), 3.81–3.78 (m, 1H, H-4″), 3.63–3.57 (m, 1H, H-5″), 3.50–3.43 (m, 1H, H-5″), 2.33 (s, 3H, CH3); 13C-NMR (DMSO-d6, 100 MHz) δ 160.31 (C=O), 155.64 (C=O), 153.25, 152.53, 151.08, 141.71, 140.95, 134.00, 132.61, 127.96, 124.08, 118.61, 117.38, 115.87, 88.29, 85.77, 70.60, 62.03, 32.65 (SCH2), 20.23 (CH3); IR (ATR) 3301 (br, OH + NH), 1720 (m, C=O), 1644 (s, C=O), 1566 (m), 1081 (s) cm−1; MS (FAB+) m/z 487 (M+, 1), 185 (9), 97 (31), 55 (100); HRMS (FAB) calcd for (C21H21N5O7S)+: 487.1162, found: 487.1162.

5. Conclusions

Four new compound sets containing 20 imidazole–coumarin conjugates were established. Experimental results indicate that five among the 20 conjugates significantly inhibited HCV subgenomic replicon replication in the Huh 5-2 cell lines. In particular, the series of 1H-imidazole conjugates (i.e., 3b, 3d, and 3e) exhibited the most appealing results, with EC50 values of 7.2, 5.1, and 8.4 μM together with SI values of 12, 15, and 21, respectively. The imidazole ring can be N-alkylated or ribosylated as well as replaced by a benzimidazole, inosine, or guanosine. Nevertheless, the parent imidazole conjugates with an N–H proton generally offers a higher SI value than those without such a proton. Moreover, incorporation of substituents into the coumarin rings can increase both potency and selectivity of the conjugates. These guidelines provide a valuable reference for medicinal scientists attempting to optimize the anti-viral compounds during the drug development stage. The mechanism of action of these conjugated compounds with significant activity towards viral enzymes will be studies in due course.

Supplementary Materials

Supplementary materials can be accessed at: https://www.mdpi.com/1420-3049/21/2/228/s1.

Acknowledgments

For financial support, we thank Ministry of Science and Technology of R.O.C. (grant No. NSC 102-2633-M-007-001 and MOST 103-2113-M-007-018-MY3), Ministry of Education of R.O.C. (grant No. 104N2011E1 and 104N2016E1), and National Central University (grant No. 103G603-14). The work in Leuven is supported by the European Commission SILVER project within the 7th Framework Program as Cooperation Project Grant Agreement (No. 260644).

Author Contributions

S.-C. Tsay and J.R. Hwu—initiation of the project, design of the compounds, writing of the paper. S.-Y. Lin, W.-C. Huang, and M.-H. Hsu—synthesis and analysis/characterization of the compounds. K. C. Hwang, C.-C. Lin, J.-C. Horng, I-C. Chen, and F.-K. Shieh—interpretation of SAR results, providing the concepts of the works. P. Leyssen—study of anti-HCV activity. J. Neyts—pharmacology evaluation, preparation of the paper.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Murphy, D.G.; Sablon, E.; Chamberland, J.; Fournier, E.; Dandavino, R.; Tremblay, C.L. Hepatitis C virus genotype 7, a new genotype originating from central Africa. J. Clin. Microbiol. 2015, 53, 967–972. [Google Scholar] [CrossRef] [PubMed]
  2. Oze, T.; Hiramatsu, N.; Mita, E.; Akuta, N.; Sakamoto, N.; Nagano, H.; Itoh, Y.; Kaneko, S.; Izumi, N.; Nomura, H.; et al. A multicenter survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. Hepatol. Res. 2013, 43, 35–43. [Google Scholar] [CrossRef] [PubMed]
  3. Kwong, A.D.; Kauffman, R.S.; Hurter, P.; Mueller, P. Discovery and development of telaprevir: An NS3–4A protease inhibitor for treating genotype 1 chronic hepatitis C virus. Nat. Biotechnol. 2011, 29, 993–1003. [Google Scholar] [CrossRef] [PubMed]
  4. Thibault, P.A.; Wilson, J.A. Targeting miRNAs to treat hepatitis C virus infections and liver pathology: Inhibiting the virus and altering the host. Pharmacol. Res. 2013, 75, 48–59. [Google Scholar] [CrossRef] [PubMed]
  5. Hulskotte, E.G.J.; Feng, H.-P.; Xuan, F.; Gupta, S.; van Zutven, M.G.J.A.; O’Mara, E.; Wagner, J.A.; Butterton, J.R. Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin. Antimicrob. Agents Chemother. 2013, 57, 2582–2588. [Google Scholar] [CrossRef] [PubMed]
  6. Orrin, E.; Barnabas, A.; Agarwal, K.; Walsh, S.A. Cutaneous side-effects of antihepatitis C treatment: The U.K. experience. Br. J. Dermatol. 2015, 172, 292–293. [Google Scholar] [CrossRef] [PubMed]
  7. U.S. Food and Drug Administration. FDA Approves First Combination Pill to Treat Hepatitis C. Available online: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm418365.htm (accessed on 10 October 2014).
  8. U.S. Food and Drug Administration. FDA Approves Viekira Pak to Treat Hepatitis C. Available online: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427530.htm (accessed on 19 December 2014).
  9. Van de Ven, N.; Fortunak, J.; Simmons, B.; Ford, N.; Cooke, G.S.; Khoo, S.; Hill, A. Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus. Hepatology 2015, 61, 1174–1182. [Google Scholar] [CrossRef] [PubMed]
  10. Tsay, S.-C.; Hwu, J.R.; Singha, R.; Huang, W.-C.; Chang, Y.H.; Hsu, M.-H.; Shieh, F.-K.; Lin, C.-C.; Hwang, K.C.; Horng, J.-C.; et al. Coumarins hinged directly on benzimidazoles and their ribofuranosides to inhibit hepatitis C virus. Eur. J. Med. Chem. 2013, 63, 290–298. [Google Scholar] [CrossRef] [PubMed]
  11. Hwu, J.R.; Singha, R.; Hong, S.-C.; Chang, Y.-H.; Das, A.R.; Vliegen, I.; de Clercq, E.; Neyts, J. Synthesis of new benzimidazole–coumarin conjugates as anti-hepatitis C virus agents. Antivir. Res. 2008, 77, 152–162. [Google Scholar] [CrossRef] [PubMed]
  12. Neyts, J.; de Clercq, E.; Singha, R.; Chang, Y.-H.; Das, A.R.; Chakraborty, S.K.; Hong, S.-C.; Tsay, S.-C.; Hsu, M.-H.; Hwu, J.R. Structure-activity relationship of new anti-hepatitis C virus agents: Heterobicycle-coumarin conjugates. J. Med. Chem. 2009, 52, 1486–1490. [Google Scholar] [CrossRef] [PubMed]
  13. Hwu, J.R.; Lin, S.-Y.; Tsay, S.-C.; de Clercq, E.; Leyssen, P.; Neyts, J. Coumarin-purine ribofuranoside conjugates as new agents against hepatitis C virus. J. Med. Chem. 2011, 54, 2114–2126. [Google Scholar] [CrossRef] [PubMed]
  14. Hwu, J.R.; Lin, S.-Y.; Tsay, S.-C.; Singha, R.; Pal, B.K.; Leyssen, P.; Neyts, J. Development of New Sulfur-Containing Conjugated Compounds as Anti-HCV Agents. Phosphorus Sulfur Silicon Relat. Elem. 2011, 186, 1144–1152. [Google Scholar] [CrossRef]
  15. Nichols, D.B.; Leão, R.A.; Basu, A.; Chudayeu, M.; de Moraes, P.F.; Talele, T.T.; Costa, P.R.; Kaushik–Basu, N. Evaluation of coumarin and neoflavone derivatives as HCV NS5B polymerase inhibitors. Chem. Biol. Drug Des. 2013, 81, 607–614. [Google Scholar] [CrossRef] [PubMed]
  16. Cervi, A.; Aillard, P.; Hazeri, N.; Petit, L.; Chai, C.L.L.; Willis, A.C.; Banwell, M.G. Total syntheses of the coumarin-containing natural products pimpinellin and fraxetin using Au(I)-catalyzed intramolecular hydroarylation (IMHA) chemistry. J. Org. Chem. 2013, 78, 9876–9882. [Google Scholar] [CrossRef] [PubMed]
  17. François, J.; Raymond, A. Small-Molecule Hepatitis C Virus (HCV) ns3/4a Serine Protease Inhibitors. WO Patent 128344 A1, 30 October 2008. [Google Scholar]
  18. Njoroge, F.G.; Chen, K.X.; Shih, N.-Y.; Piwinski, J.J. Challenges in modern drug discovery: A case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection. Acc. Chem. Res. 2008, 41, 50–59. [Google Scholar] [CrossRef] [PubMed]
  19. Lin, C.; Kwong, A.D.; Perni, R.B. Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3.4A serine protease. Infect. Disord. Drug Targets 2006, 6, 3–16. [Google Scholar] [CrossRef] [PubMed]
  20. Khabnadideh, S.; Rezaei, Z.; Khalafi–Nezhad, A.; Bahrinajafi, R.; Mohamadi, R.; Farrokhroz, A.A. Synthesis of N-alkylated derivatives of imidazole as antibacterial agents. Bioorg. Med. Chem. Lett. 2003, 13, 2863–2865. [Google Scholar] [CrossRef]
  21. Bhatnagar, A.; Sharma, P.K.; Kumar, N. A review on “imidazoles”: Their chemistry and pharmacological potentials. Int. J. Pharmtech Res. 2011, 3, 268–282. [Google Scholar]
  22. Chen, J.; Wang, Z.; Li, C.M.; Lu, Y.; Vaddady, P.K.; Meibohm, B.; Dalton, J.T.; Miller, D.D.; Li, W. Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents. J. Med. Chem. 2010, 53, 7414–7427. [Google Scholar] [CrossRef] [PubMed]
  23. Sharma, D.; Narasimhan, B.; Kumar, P.; Judge, V.; Narang, R.; de Clercq, E.; Balzarini, J. Synthesis, antimicrobial and antiviral evaluation of substituted imidazole derivatives. Eur. J. Med. Chem. 2009, 44, 2347–2353. [Google Scholar] [CrossRef] [PubMed]
  24. Lagoja, I.M.; Pannecouque, C.; van Aerschot, A.; Witvrouw, M.; Debyser, Z.; Balzarini, J.; Herdewijn, P.; de Clercq, E. N-Aminoimidazole derivatives inhibiting retroviral replication via a yet unidentified mode of action. J. Med. Chem. 2003, 46, 1546–1553. [Google Scholar] [CrossRef] [PubMed]
  25. Scheiner, S.; Yi, M. The proton transfer properties of imidazole. J. Phys. Chem. 1996, 100, 9235–9241. [Google Scholar] [CrossRef]
  26. Chen, J.; Li, C.-M.; Wang, J.; Ahn, S.; Wang, Z.; Lu, Y.; Dalton, J.T.; Miller, D.D.; Li, W. Synthesis and antiproliferative activity of novel 2-aryl-4-benzoyl-imidazole derivatives targeting tubulin polymerization. Bioorg. Med. Chem. 2011, 19, 4782–4795. [Google Scholar] [CrossRef] [PubMed]
  27. Fasciano, J.; Steele, T.; Castagnoli, N.; Katz, J.; Ricaurte, G. The effect of N-methylation on fenfluramine’s neurotoxic and pharmacologic actions. Brain Res. 1997, 763, 182–190. [Google Scholar] [CrossRef]
  28. Zai, L.; Ferrari, C.; Subbaiah, S.; Havton, L.A.; Coppola, G.; Strittmatter, S.; Irwin, N.; Geschwind, D.; Benowitz, L.I. Inosine alters gene expression and axonal projections in neurons contralateral to a cortical infarct and improves skilled use of the impaired limb. J. Neurosci. 2009, 29, 8187–8197. [Google Scholar] [CrossRef] [PubMed]
  29. Liaudet, L.; Mabley, J.G.; Pacher, P.; Virag, L.; Soriano, F.G.; Marton, A.; Haskó, G.; Deitch, E.A.; Szabó, C. Inosine exerts a broad range of anti-inflammatory effects in a murine model of acute lung injury. Ann. Surg. 2002, 235, 568–578. [Google Scholar] [CrossRef] [PubMed]
  30. Cianciara, J.; Laskus, T.; Gabinska, E.; Loch, T. Isoprinosine in the treatment of chronic active hepatitis type B. Scand. J. Infect. Dis. 1990, 22, 645–648. [Google Scholar] [CrossRef] [PubMed]
  31. Kowalik-Mikołajewska, B. Course of chronic virus hepatitis B in children and attempts at modifying its treatment. Pol. Tyg. Lek. 1993, 48, 258–260. [Google Scholar] [PubMed]
  32. Njei, B.; Garg, S.K.; Kenta-Bibi, E.; Kongnyuy, E.J.; Alam, S.E. Isoprinosine for chronic hepatitis B. Cochrane Database Syst. Rev. 2014. [Google Scholar] [CrossRef]
  33. Giuliani, P.; Romano, S.; Ballerini, P.; Ciccarelli, R.; Petragnani, N.; Cicchitti, S.; Zuccarini, M.; Jiang, S.; Rathbone, M.P.; Caciagli, F.; et al. Protective activity of guanosine in an in vitro model of Parkinson’s disease. Panminerva Med. 2012, 54, 43–51. [Google Scholar] [PubMed]
  34. Sizun, G.; Pierra, C.; Peyronnet, J.; Badaroux, E.; Rabeson, C.; Benzaria-Prad, S.; Surleraux, D.; Loi, A.G.; Musiu, C.; Liuzzi, M.; et al. Design, synthesis and antiviral evaluation of 2′-C-methyl branched guanosine pronucleotides: The discovery of IDX184, a potent liver-targeted HCV polymerase inhibitor. Future Med. Chem. 2015, 7, 1675–1700. [Google Scholar] [CrossRef] [PubMed]
  35. Ali-von Laue, C.; Zoschke, C.; Do, N.; Lehnen, D.; Küchler, S.; Mehnert, W.; Blaschke, T.; Kramer, K.D.; Plendl, J.; Weindl, G.; et al. Improving topical non-melanoma skin cancer treatment: In vitro efficacy of a novel guanosine-analog phosphonate. Skin Pharmacol. Physiol. 2014, 27, 173–180. [Google Scholar] [CrossRef] [PubMed]
  36. Simons, C.; Wu, Q.; Htar, T.T. Recent advances in antiviral nucleoside and nucleotide therapeutics. Curr. Top. Med. Chem. 2005, 5, 1191–1203. [Google Scholar] [CrossRef] [PubMed]
  37. Chien, T.C.; Saluja, S.S.; Drach, J.C.; Townsend, L.B. Synthesis and antiviral evaluation of polyhalogenated imidazole nucleosides: Dimensional analogues of 2,5,6-trichloro-1-(β-d-ribofuranosyl)- benzimidazole. J. Med. Chem. 2004, 47, 5743–5752. [Google Scholar] [CrossRef] [PubMed]
  38. Bhan, P.; Bhan, A.; Hong, M.; Hartwell, J.G.; Saunders, J.M.; Hoke, G.D. 2′,5′-Linked oligo-3′-deoxyribonucleoside phosphorothioate chimeras: Thermal stability and antisense inhibition of gene expression. Nucleic Acids Res. 1997, 25, 3310–3317. [Google Scholar] [CrossRef] [PubMed]
  39. Chávez–Gil, T.E.; Meléndez, E. Synthesis, spectroscopic and electrochemical characterization of water soluble [(η5-C5H5)2Mo(thionucleobase/thionucleoside)]Cl2 complexes. Inorg. Chim. Acta 2004, 357, 1092–1102. [Google Scholar] [CrossRef]
  40. Lin, T.-S.; Cheng, J.-C.; Ishiguro, K.; Sartorelli, A.C. Purine and 8-substituted purine arabinofuranosyl and ribofuranosyl nucleoside derivatives as potential inducers of the differentiation of the Friend erythroleukemia. J. Med. Chem. 1985, 28, 1481–1485. [Google Scholar] [CrossRef] [PubMed]
  41. Lin, T.-S.; Cheng, J.-C.; Ishiguro, K.; Sartorelli, A.C. 8-Substituted guanosine and 2′-deoxyguanosine derivatives as potential inducers of the differentiation of Friend erythroleukemia cells. J. Med. Chem. 1985, 28, 1194–1198. [Google Scholar] [CrossRef] [PubMed]
  42. Silverstein, R.M.; Webster, F.X.; Kiemle, D.J. Spectrometric Identification of Organic Compounds, 7th ed.; John Wiley: New York, NY, USA, 2005; pp. 92–94. [Google Scholar]
  43. Vorbrüggen, H.; Krolikiewicz, K.; Bennua, B. Nucleoside syntheses, XXII Nucleoside synthesis with trimethylsilyl triflate and perchlorate as catalysts. Chem. Ber. 1981, 114, 1234–1255. [Google Scholar] [CrossRef]
  44. Al Mourabit, A.; Beckmann, M.; Poupat, C.; Ahond, A.; Potier, P. New C2 symmetrical and semisymmetrical substituted imidazolium ribonucleoside. Imidazolic nucleosides analogues. Tetrahedron Asymmetry 1996, 7, 3455–3464. [Google Scholar] [CrossRef]
  45. Lohmann, V.; Körner, F.; Koch, J.-O.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285, 110–113. [Google Scholar] [CrossRef] [PubMed]
  46. Paeshuyse, J.; Kaul, A.; de Clercq, E.; Rosenwirth, B.; Dumont, J.-M.; Scalfaro, P.; Bartenschlager, R.; Neyts, J. The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro. Hepatology 2006, 43, 761–770. [Google Scholar] [CrossRef] [PubMed]
  47. Kaye, P.T.; Musa, M.A. A convenient and improved Baylis-Hillman synthesis of 3-substituted 2H-1-benzopyran-2-ones. Synthesis 2002, 2701–2706. [Google Scholar] [CrossRef]
  48. Gosselin, G.; Imbach, J.L.; Townsend, L.B.; Panzica, R.P. The synthesis of imidazole-2-thione nucleosides. J. Heterocycl. Chem. 1979, 16, 1185–1191. [Google Scholar] [CrossRef]
  • Sample Availability: Samples of all conjugated compounds are available from the authors.
Molecules 21 00228 g001 550
Figure 1. General structure of targed imidazole–coumarin conjugates.
Figure 1. General structure of targed imidazole–coumarin conjugates.
Molecules 21 00228 g001
Molecules 21 00228 g003 550
Scheme 1. Synthesis of imidazole–coumarin conjugates.
Scheme 1. Synthesis of imidazole–coumarin conjugates.
Molecules 21 00228 g003
Molecules 21 00228 g004 550
Scheme 2. Synthesis of (1-ribofuranosyl)imidazole–coumarin conjugates.
Scheme 2. Synthesis of (1-ribofuranosyl)imidazole–coumarin conjugates.
Molecules 21 00228 g004
Molecules 21 00228 g005 550
Scheme 3. Synthesis of inosine– and guanosine-coumarin conjugates.
Scheme 3. Synthesis of inosine– and guanosine-coumarin conjugates.
Molecules 21 00228 g005
Molecules 21 00228 g002 550
Figure 2. Structure of benzimidazole–coumarin conjugates.
Figure 2. Structure of benzimidazole–coumarin conjugates.
Molecules 21 00228 g002
Table
Table 1. Anti-metabolic and antiviral effect of conjugated compounds on HCV 1b subgenomic replicon replication in Huh 5-2 cells.
Table 1. Anti-metabolic and antiviral effect of conjugated compounds on HCV 1b subgenomic replicon replication in Huh 5-2 cells.
Compound aCC50 b (μM)EC50 c (μM)SI d
3a122304.1
3b837.212
3c859.78.8
3d755.115
3e1738.421
3f496.77.3
3g75155.1
7a128592.2
7b122264.7
7c85146.3
7d107195.7
7e119343.5
9a109611.8
9b105731.4
9d93701.3
9e1021021.0
9f1061061.0
11b1021021.0
11e99991.0
11f1031031.0
12a e [11]90273.4
12d e [11]424.010
12e e [11]27102.8
coumarin>500>150-
imidazole>500>150-
a Interferon α-2b was used as a (positive) reference compound at 10,000 units/well and reduced the signal in the viral RNA (luciferase) assay to background levels. The values were obtained as the average of triplicate determinations; b The concentration of a compound with an adverse effect of 50% was observed on the host cell metabolism, as determined by the MTS method; c The concentration of a compound at which virus replication was inhibited by 50% was observed, as determined by real-time quantitative RT-PCR; d Selectivity index (ratio of CC50 to EC50); e Reference known compounds published in [11].

Share and Cite

MDPI and ACS Style

Tsay, S.-C.; Lin, S.-Y.; Huang, W.-C.; Hsu, M.-H.; Hwang, K.C.; Lin, C.-C.; Horng, J.-C.; Chen, I.-C.; Hwu, J.R.; Shieh, F.-K.; et al. Synthesis and Structure-Activity Relationships of Imidazole-Coumarin Conjugates against Hepatitis C Virus. Molecules 2016, 21, 228. https://doi.org/10.3390/molecules21020228

AMA Style

Tsay S-C, Lin S-Y, Huang W-C, Hsu M-H, Hwang KC, Lin C-C, Horng J-C, Chen I-C, Hwu JR, Shieh F-K, et al. Synthesis and Structure-Activity Relationships of Imidazole-Coumarin Conjugates against Hepatitis C Virus. Molecules. 2016; 21(2):228. https://doi.org/10.3390/molecules21020228

Chicago/Turabian Style

Tsay, Shwu-Chen, Shu-Yu Lin, Wen-Chieh Huang, Ming-Hua Hsu, Kuo Chu Hwang, Chun-Cheng Lin, Jia-Cherng Horng, I-Chia Chen, Jih Ru Hwu, Fa-Kuen Shieh, and et al. 2016. "Synthesis and Structure-Activity Relationships of Imidazole-Coumarin Conjugates against Hepatitis C Virus" Molecules 21, no. 2: 228. https://doi.org/10.3390/molecules21020228

Article Metrics

Back to TopTop